The University of Southampton
University of Southampton Institutional Repository

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment
Previous antiresorptive (AR) treatment may influence the response to teriparatide. We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo. Patients were divided into three groups based on their prior AR treatment: treatment-naive (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractures, persistent low BMD, and/or significant BMD loss while on therapy. Changes in BMD from baseline were analyzed using mixed model repeated measures. Lumbar spine BMD increased significantly from baseline at 6, 12, 18, and 24 mo in all three groups. The mean gain in spine BMD over 24 mo was greater in the treatment-naive group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups. The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively. Early decreases in hip BMD in the inadequate AR responder group were reversed by 18 mo of treatment. Increases in BMD between 18 and 24 mo were highly significant. Nausea (13.3%) and arthralgia (11.7%) were the most commonly reported adverse events. Asymptomatic hypercalcemia was reported in 5.0% of patients. Teriparatide treatment for 24 mo is associated with a significant increase in BMD in patients with and without previous AR use. Prior AR treatment modestly blunted the BMD response to teriparatide. Safety was consistent with current prescribing label information
photon, middle aged, postmenopausal women, postmenopause, bone density conservation agents, fracture, therapy, hip, fractures, trial, bone density, research, women, adverse effects, drug therapy, agent, prospective studies, female, osteoporosis, spine, bone, humans, teriparatide, aged, lumbar vertebrae, drug effects, therapeutic use, pharmacology, absorptiometry
0884-0431
1591-1600
Obermayer-Pietsch, B. M.
056b8982-5cf7-47be-aa06-e7b831ee3377
Marin, F.
5431b356-3386-42d5-8d4f-570a4e2ce271
McCloskey, E. V.
e968a69f-27b8-4568-987d-5d8dbbdff3fd
Hadji, P.
2688aa87-91b1-4f68-9d29-d8a191b9fabd
Farrerons, J.
f271b3c2-67de-4864-8045-0944902cb5f3
Boonen, S.
19c70ece-493f-4b7c-9bf9-5e4a4a887ba4
Audran, M.
9bb760c1-5b65-4486-9404-8314d7b9f3ac
Barker, C.
39890323-84b1-46d6-97da-3f0f9f3a3989
Anastasilakis, A. D.
78b6402d-f8f2-438a-80cf-0995a3570209
Fraser, W. D.
d47997f8-03b1-4ddf-b1be-adefa75add75
Nickelsen, T.
d1594cad-a0e9-42f7-b47c-0db01ff36a65
Obermayer-Pietsch, B. M.
056b8982-5cf7-47be-aa06-e7b831ee3377
Marin, F.
5431b356-3386-42d5-8d4f-570a4e2ce271
McCloskey, E. V.
e968a69f-27b8-4568-987d-5d8dbbdff3fd
Hadji, P.
2688aa87-91b1-4f68-9d29-d8a191b9fabd
Farrerons, J.
f271b3c2-67de-4864-8045-0944902cb5f3
Boonen, S.
19c70ece-493f-4b7c-9bf9-5e4a4a887ba4
Audran, M.
9bb760c1-5b65-4486-9404-8314d7b9f3ac
Barker, C.
39890323-84b1-46d6-97da-3f0f9f3a3989
Anastasilakis, A. D.
78b6402d-f8f2-438a-80cf-0995a3570209
Fraser, W. D.
d47997f8-03b1-4ddf-b1be-adefa75add75
Nickelsen, T.
d1594cad-a0e9-42f7-b47c-0db01ff36a65

Obermayer-Pietsch, B. M., Marin, F., McCloskey, E. V., Hadji, P., Farrerons, J., Boonen, S., Audran, M., Barker, C., Anastasilakis, A. D., Fraser, W. D. and Nickelsen, T. (2008) Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. Journal of Bone and Mineral Research, 23 (10), 1591-1600. (doi:10.1359/jbmr.080506).

Record type: Article

Abstract

Previous antiresorptive (AR) treatment may influence the response to teriparatide. We examined BMD response and safety in a subgroup of 503 postmenopausal women with osteoporosis who received teriparatide for 24 mo. Patients were divided into three groups based on their prior AR treatment: treatment-naive (n = 84); pretreated with no evidence of inadequate treatment response (n = 134); and pretreated showing an inadequate response to AR treatment (n = 285), which was predefined based on the occurrence of fractures, persistent low BMD, and/or significant BMD loss while on therapy. Changes in BMD from baseline were analyzed using mixed model repeated measures. Lumbar spine BMD increased significantly from baseline at 6, 12, 18, and 24 mo in all three groups. The mean gain in spine BMD over 24 mo was greater in the treatment-naive group (0.095 g/cm(2); 13.1%) than in the AR pretreated (0.074 g/cm(2); 10.2%; p < 0.005) and inadequate AR responder (0.071 g/cm(2); 9.8%; p < 0.001) groups. The corresponding increases in total hip BMD were 3.8%, 2.3%, and 2.3%, respectively. Early decreases in hip BMD in the inadequate AR responder group were reversed by 18 mo of treatment. Increases in BMD between 18 and 24 mo were highly significant. Nausea (13.3%) and arthralgia (11.7%) were the most commonly reported adverse events. Asymptomatic hypercalcemia was reported in 5.0% of patients. Teriparatide treatment for 24 mo is associated with a significant increase in BMD in patients with and without previous AR use. Prior AR treatment modestly blunted the BMD response to teriparatide. Safety was consistent with current prescribing label information

This record has no associated files available for download.

More information

Published date: 2008
Keywords: photon, middle aged, postmenopausal women, postmenopause, bone density conservation agents, fracture, therapy, hip, fractures, trial, bone density, research, women, adverse effects, drug therapy, agent, prospective studies, female, osteoporosis, spine, bone, humans, teriparatide, aged, lumbar vertebrae, drug effects, therapeutic use, pharmacology, absorptiometry

Identifiers

Local EPrints ID: 70490
URI: http://eprints.soton.ac.uk/id/eprint/70490
ISSN: 0884-0431
PURE UUID: 9a8bd36b-9ca4-423d-aab1-5230e328195c

Catalogue record

Date deposited: 12 Feb 2010
Last modified: 13 Mar 2024 20:04

Export record

Altmetrics

Contributors

Author: B. M. Obermayer-Pietsch
Author: F. Marin
Author: E. V. McCloskey
Author: P. Hadji
Author: J. Farrerons
Author: S. Boonen
Author: M. Audran
Author: C. Barker
Author: A. D. Anastasilakis
Author: W. D. Fraser
Author: T. Nickelsen

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×